文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

心脏手术中的冷藏与室温血小板:CHIPS随机临床试验

Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论心脏手术体外循环后活动性出血患者中,冷藏血小板储存至21天的止血效果不劣于室温血小板。

CHIPS为3期、多中心、随机、部分盲法、适应性、非劣效、储存时长范围试验,在美国和澳大利亚27个中心纳入儿童和成人计划体外循环心脏手术患者,2021年12月至2025年3月。患者按2:1随机接受冷藏血小板(最长21天)或室温血小板(最长7天)。主要终点止血效果评分(1-5分,越高出血越重)非劣效界值1分;冷藏血小板在所有储存时长下非劣效概率>99.9%,合并均差0.09(95%可信区间-0.06至0.23)。24小时胸管引流量无统计学差异;除冷藏组再探查率增加外,血栓事件、输血相关不良事件、ARDS、肾衰竭、脓毒性休克和死亡率无差异。

要点

  • 心脏手术体外循环后活动性出血患者中,冷藏血小板储存至21天止血效果不劣于室温血小板,非劣效概率>99.9%。
  • 主要终点止血效果评分合并均差0.09(95%可信区间-0.06至0.23),非劣效界值1分。
  • 24小时胸管引流量中位数冷藏组8.9 mL/kg vs 室温组8.4 mL/kg,中位数差0.4(95%CI -1.0至1.5),无统计学差异。
  • 冷藏组再探查率增加;静脉或动脉血栓事件、输血相关不良事件、ARDS、肾衰竭、脓毒性休克和死亡率两组无差异。
  • 作者认为使用冷藏血小板可能通过减少浪费和短缺增加血小板可及性。

适用人群与场景

  • 美国、澳大利亚27个中心,儿童和成人计划体外循环心脏手术患者,2021年12月至2025年3月。
  • 纳入接受血小板输注的患者:1000例中989例纳入主要分析(冷藏组650例,室温组339例);平均(SD)年龄42.1(30.1)岁,67.8%为男性。

诊断标准与关键阈值

  • 主要终点止血效果评分范围1-5分,分值越高表示出血越重;非劣效界值1分。
  • 成功标准:至少1个≥7天的冷藏储存时长非劣效后验概率≥97.5%。

研究设计与关键结果

  • 3期、多中心、随机、部分盲法、适应性、非劣效、储存时长范围试验;1000例接受血小板输注,989例纳入主要分析(冷藏组650例 vs 室温组339例)。
  • 干预:按2:1随机接受冷藏血小板(最长21天储存)vs 室温血小板(最长7天储存)。
  • 主要终点:冷藏血小板所有储存时长非劣效概率>99.9%;合并均差0.09(95%可信区间-0.06至0.23)。
  • 次要终点:24小时胸管引流量中位数(IQR)冷藏组8.9 mL/kg(5.2-15.4)vs 室温组8.4 mL/kg(5.5-15.9),中位数差0.4(95%CI -1.0至1.5),无统计学差异。
  • 事后分析:止血效果评分均值(SD)冷藏组3.08(1.15)vs 室温组2.99(1.10)。
  • 静脉或动脉血栓事件、输血相关不良事件、ARDS、肾衰竭、脓毒性休克和死亡率两组无差异,但冷藏组再探查率增加。

证据类型、等级与局限

  • 证据类型:3期、多中心、随机、部分盲法、适应性、非劣效、储存时长范围试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对心脏手术患者,冷藏储存至21天的血小板在控制活动性手术出血方面不劣于室温血小板。
  • 作者认为,使用冷藏血小板可能通过减少浪费和短缺增加血小板可及性。
  • 作者认为,使用冷藏血小板可能使血小板纳入因室温血小板5-7天保质期而无法维持血小板的场所的库存。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Patients undergoing cardiac surgery with cardiopulmonary bypass often require platelet transfusions for bleeding. Platelets are routinely stored at room temperature (20-24 °C) for up to 5 to 7 days; however, cold storage (1-6 °C) may allow for increased storage duration without loss of hemostatic function.

OBJECTIVE: To determine the maximum cold-storage duration, up to 21 days, for which cold-stored platelets (CSPs) are noninferior or superior in hemostatic efficacy to room-temperature platelets (RTPs) when transfused in actively bleeding patients undergoing cardiac surgery with cardiopulmonary bypass.

DESIGN, SETTING, AND PARTICIPANTS: A phase 3, multicenter, randomized, partially blinded, adaptive, noninferiority, storage duration-ranging trial conducted in pediatric and adult patients undergoing cardiac surgery with planned cardiopulmonary bypass at 27 sites in the US and Australia from December 2021 to March 2025. Statistical analysis was conducted from September 9 to October 3, 2025.

INTERVENTION: Patients were randomized 2:1 to receive CSPs with a maximum of 21 days of storage vs RTPs with a maximum of 7 days of storage.

MAIN OUTCOMES AND MEASURES: The primary outcome was a hemostatic efficacy score with values ranging from 1 to 5 and higher values indicating greater bleeding. The noninferiority margin was 1 point. The success criterion was met if at least 1 cold-storage duration of 7 days or more had a posterior probability of noninferiority of at least 97.5%. The secondary outcome was 24-hour chest tube output.

RESULTS: Of the 1000 patients who underwent platelet transfusion, 989 were included in the primary analysis (650 CSPs and 339 RTPs). The cohort had a mean (SD) age of 42.1 (30.1) years and 67.8% were male. CSPs were noninferior to RTPs for the primary outcome, with a probability of greater than 99.9% for all cold-storage durations. Pooled across storage durations, CSPs had a mean difference from RTPs of 0.09 (95% credible interval, -0.06 to 0.23). Median (IQR) chest tube output at 24 hours (8.9 mL/kg [5.2-15.4] for CSPs vs 8.4 mL/kg [5.5-15.9] for RTPs; difference in medians, 0.4 [95% CI, -1.0 to 1.5]) was not statistically different between study groups. In a post hoc analysis, as all storage durations were noninferior, considering the CSPs as a single group, the hemostatic efficacy score was similar between both groups: mean (SD) of 3.08 (1.15) CSPs vs 2.99 (1.10) RTPs. There were no differences in venous or arterial thrombotic events, transfusion-associated adverse events, acute respiratory distress syndrome, kidney failure, septic shock, and mortality between the study groups, except for increased reexploration rates in the CSP group.

CONCLUSIONS AND RELEVANCE: For patients undergoing cardiac surgery, CSPs stored up to 21 days are noninferior to RTPs for the control of active surgical bleeding. Use of CSPs may allow for increased availability of platelets by reducing wastage and shortages and may allow for incorporation of platelets into inventory at locations where platelets cannot be maintained due to the 5- to 7-day shelf life of RTPs.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04834414.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Spinella PC, Zantek ND, VanBuren JM, et al. Cold and Room-Temperature Platelets in Cardiac Surgery: The CHIPS Randomized Clinical Trial. JAMA. 2026. PMID: 42606886. doi:10.1001/jama.2026.13328

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。